Company Overview of Relypsa, Inc.
Relypsa, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of polymeric medicines for patients with conditions that are overlooked and undertreated and can be addressed in the gastrointestinal tract primarily in the United States. The company offers Veltassa (patiromer), a non-absorbed potassium binding polymer for the treatment of hyperkalemia. It has license agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. for developing and commercializing Veltassa outside the United States and Japan. The company was founded in 2007 and is headquartered in Redwood City, California. As of August 31, 2016, Relypsa, Inc. operates as a subsidiary of V...
100 Cardinal Way
Redwood City, CA 94063
Founded in 2007
Key Executives for Relypsa, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Accounting Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President
Chief Medical Officer and Senior Vice President
Chief Commercial Officer and Senior Vice President
Compensation as of Fiscal Year 2016.
Relypsa, Inc. Key Developments
Relypsa Files Form 15
Sep 12 16
Relypsa, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, par value $0.001 per share under the Securities Exchange Act of 1934, as amended.
Relypsa, Inc.(NasdaqGM:RLYP) dropped from NASDAQ Biotechnology Index
Sep 6 16
Relypsa, Inc. has been removed from NASDAQ Biotech Index.
Relypsa Suspends Its Trading Of The Common Stock From NASDAQ
Sep 1 16
On July 21, 2016, Relypsa, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 20, 2016, with Galenica AG, a public limited company existing under the laws of Switzerland (“Parent”), and Vifor Pharma USA Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”). On September 1, 2016, Relypsa notified The NASDAQ Global Market (“NASDAQ”) of the consummation of the Merger and requested that NASDAQ (i) suspend trading of the Common Stock before the opening of trading on September 1, 2016 and (ii) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Relypsa intends to file with the SEC a certification on Form 15 under the Exchange Act, requesting the deregistration of the Common Stock and the suspension of Relypsa’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 21, 2016
April 27, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries